Supernus Pharmaceuticals | SUPN - Gross Profit On Sales

Stock Price
51.65
Daily Change
2.28 4.62%
Monthly
0.80%
Yearly
34.51%
Q1 Forecast
46.68

Supernus Pharmaceuticals reported $148.81M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 203.04M 12.04M Sep/2025
Eisai JPY 151.84B 8.21B Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 148.81M 21.01M Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025